Frequency of Multi-Drug Resistant Enterobacter Species Isolated from Patients with Different Clinical Manifestations in Khartoum State, Sudan

Hiba Abdel Salam. A. Mahgoub1*, Tyseer A.A. Mahgoub2, Osama M. M. Khair3,4, Mawada H.F. Mohammed5, Maye M. Merghani6, Majdolin L.M. AlBushra4, Elsadig M. Hamdan7, Hisham N. Altyah1,8, Hind H. Ahmed1, and Mogahid M. Elhassan1,9.

1-Department of Medical Microbiology, College of Medical Laboratory Science, Sudan University of Science and Technology, Sudan.
2-Fetomaternal center-Doha-Qatar
3-National University Biomedical Institute, National University, Sudan.
4-Oczon Laboratory of Molecular Biology, Khartoum, Sudan.
5-Department of Medical Microbiology, Yastabshiroon Hospital, Sudan
6-Medical Laboratory Science program, AlNahta College, Sudan.
7-Department of Medical Microbiology, College of Medical Laboratory Science, University of Gezira, Sudan.
8-Biochemistry Department, Faculty of Sciences, King Abdulaziz University, Jeddah 21452, Saudi Arabia
9-Nahrain College, Khartoum, Sudan.

*E.Mail: hibaam24@hotmail.com

ARTICLE INFO

ABSTRACT

Enterobacter species are members of ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species) which are described as the leading cause of resistant nosocomial infections. Objectives: The present study aimed to estimate the frequency of Multi-Drug resistant Enterobacter species isolated from Patients with different Clinical manifestations in Khartoum state, Sudan. Methods: A cross-sectional laboratory-based study was conducted from February 2021 to October 2021. To isolate and identify Enterobacter species from different clinical specimens by conventional cultural methods, and to determine the antimicrobial profile of Enterobacter species by Kirby–Bauer disc diffusion technique. Result: A total of three hundred and eighty-four (n=384) different clinical specimens (urine 232(60%), wound swab 61 (16%), sputum 19(5%), and blood 72 (19%) specimens were collected from Yastabshiroon Hospital, Khartoum, 129(33.6%), Ribat Teaching Hospital, Khartoum, 255(66.4%), 173 (45.0%) were from males, while 212 (55.0%) from females, among 154(40%) bacterial isolate 22(14.3%) were identified as Enterobacter spp. All Enterobacter spp isolates (100%) were multidrug resistant, The Prevalence rates of resistance of the isolates among antibiotic classes were as follows; (Penicillin 100%, Cephalosporin 96.4%, Tetracycline group 100%, Aminoglycosides 47.7%, Sulfonamides and trimethoprin 86.4%, Nitrofurant 100%, Quinolone 72.75%, Glycopeptides 100%, Chloramphenicol 100%, Tetracycline 81.8% and Carbapenem 52.3%). Conclusion: This study is the first study reporting the frequency of Multi-drug resistance Enterobacter species in Sudan. The results of this study indicated the high prevalence of Enterobacter species resistant to the majority of assessed antibiotics, and high prevalence rates of carbapenemase and ESBL-producing Enterobacter species in Khartoum- Sudan.
INTRODUCTION

The genus *Enterobacter* includes facultative anaerobic Gram-negative bacilli that are 2 mm long, motile by peritrichous flagella and belong to the family *Enterobacteriaceae*. Several strains of these bacteria are pathogenic and cause opportunistic infections in immunocompromised (Adeolu et al., 2016). It was first described in 1960, but changes in taxonomy have occurred in the last 50 years (Anne P et al., 2019). For example, *E. sakazakii* has been reassigned to a new genus *Cronobacter* (Anne P et al., 2019).

*Enterobacter* spp are natural commensals of the animal and human gut microbiota. Among these bacteria, only certain subspecies/species have been associated with hospital-acquired infections and outbreaks (Akbari M et al., 2015).

*Enterobacter* infections can include bacteremia, lower respiratory tract infections, skin and soft-tissue infections, urinary tract infections, endocarditis, intra-abdominal infections, septic arthritis, osteomyelitis, central nervous system infections, and ophthalmic infections (Mezzatesta et al., 2012). Urinary and respiratory tracts are the most common sites of infection. *Enterobacter* infections do not produce a unique enough clinical presentation to differentiate them clinically from other acute bacterial infections (Mezzatesta et al., 2012).

*Enterobacter* species are members of ESKAPE (*Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa* and *Enterobacter* species) which are described as the leading cause of resistant nosocomial infections (Akbari M et al., 2015), (Wu W, Feng Y, Zong Z. 2018). *Enterobacter aerogenes, E. cloacae* and *E. hormaechei* represent the most frequently isolated species described in clinical infections, especially in immunocompromised patients and those hospitalized in an ICU (Intensive Care Unit), due to the adaptation of these species to antimicrobial agents and their behavior as opportunistic pathogens. Several hospital outbreaks have been reported in Europe since the mid-1990s, and the wide use of extensive broad-spectrum antibiotics has stimulated the spread of resistant clones (Anne P et al., 2019). These pathogens are frequently associated with a multidrug-resistance phenotype, mainly due to their adaptation to the hospital environment and the pathogens’ ability to easily acquire numerous genetic mobile elements containing resistance and virulence genes, which make their treatment difficult (Davin-Regli A, Pagès JM. 2015), (Davin-Regli A, Masi M, et al., 2016). Antibiotic resistance, regulation of resistant genes and the clinical implications of these situations have been extensively studied (Anne P et al., 2019).

The accurate identification of species and subspecies remains a challenge. The development of genome sequencing has rapidly modified the phylogeny of the genus, particularly that of the *E. cloacae* complex (Izdebski R et al., 2015).

Pathogenicity/virulence of this bacterium remains rather unclear due to the limited number of works performed to date in this field. In contrast, its resistance against antibacterial agents has been extensively studied. In the face of antibiotic treatment, it is able to manage different mechanisms of resistance via various local and global regulator genes and the modulation of the expression of different proteins, including enzymes (β-lactamases, etc.) or membrane transporters, such as porins and efflux pumps (Anne P et al., 2019).

β-lactam antibiotics, third-generation cephalosporins and carbapenems, are used to treat infections caused by several species of *Enterobacter* (Peymani et al., 2014). β-lactamase enzymes, including extended-spectrum β-lactamases (ESBLs) and AmpC, are involved in the mechanism underlying resistance to β-lactam antibiotics in *Enterobacter* spp (Mohd Khari et al., 2016).
MATERIALS AND METHODS

Study Design, Duration, and Population:
A cross-sectional laboratory-based study was conducted from February 2021 to October 2021. This study was conducted at Yastabshiroon Hospital and Ribat Teaching Hospital in Khartoum State, Sudan. The specimen was collected from Sudanese patients who were expected to have bacterial infections and had been examined by a physician. A total of three hundred and eighty-four (n=384) different clinical specimens (urine, wound swab, sputum, and blood) were collected in sterile containers.

Sampling Technique:
This study is based on the non-probability convenience sampling technique.

Ethical Clearance:
The study proposal was approved by the ethical board of Sudan University of Science and Technology and Research Committee, Ministry of Health. Informed consent was taken from each patient before enrollment into the study.

Isolation and Identification Schemes:
MacConkey agar media and Chromogenic agar media (Liofilchem Co. Italy) were used for the isolation of Enterobacter isolates. The medium was prepared and the plate was inoculated from urine, wound swabs, sputum specimens, and blood culture media, then the plates were incubated overnight at 37°C. The isolate was identified according to lactose fermentation on MacConkey agar and the color produced on Chromogenic media. The Enterobacter species was lactose fermented and produced pink color in MacConkey agar media and produced green color in Chromogenic agar media (Liofilchem Co. Italy).

The Gram’s stain and Biochemical tests for Gram-negative bacteria (Catalase test, Oxidase test, kiligler Iron agar test, Motility test, Citrate utilization test, Urea hydrolysis test, and Indol test) were used to confirm the identity of isolates. Isolates were identified based on colonial morphology, motility, Gram’s staining, oxidase and biochemical reactions.

Antimicrobial Susceptibility test

Enterobacter Species:
The susceptibility of isolates was determined by the agar diffusion method, using a modification of the Kirby-Bauer disc diffusion technique according to CLSI guidelines (CLSI, 2018). The following antibiotic discs (drug concentrations in μg) were used: Amikacin (30), Amoxicillin (30), Amoxyclov (30), Ciprofloxacin (5), Ceftriaxone (30), Cephotaxime (30), Ceftazidime (30), Cefotaxime (30), Cefepime (30), Chloramphnicol (30), Co-trimoxazole (30), Nitrofuratoin (30), Vancomycin (30), Tetracycline (30), Gentamicin (30), Imipenem (30), and Colistin. Enterobacter-like isolates from an overnight culture were used for the sensitivity test. A colony of the isolate was picked with a straight sterile wire, inoculated into sterile 5 ml peptone water, and shaken to dissolve it. The turbidity of the suspension was matched against 0.5 McFarland standards. Poured on a sterile Mueller-Hinton agar plate. The inoculated agar plate was swayed gently to ensure that the whole agar surface was covered. The plate was drained to remove excess fluid. The antibiotic discs were placed on the agar surface, leaving a space of 25mm between them, and pressed slightly to ensure sufficient contact with the agar surface. The plates were then incubated at 37 °C for 24 h. The plates were incubated inverted in the incubator at 37°C overnight. The plates were examined for inhibition zone size. Positive control (Enterobacter ATCC25922) and negative control (E. coli ATCC25922) were used to confirm the results.

Extended-spectrum β-lactamases (ESBLs) Confirmatory Test:
The presence of ESBLs was confirmed by Phenotypic Confirmatory Test method (PCT). The CLSI-ESBL phenotypic confirmatory test with Ceftazidime 30 μg, Cefotaxime 30 μg and Cefepime 30 μg was performed for all positive isolates by disc diffusion method on Mueller-Hinton agar plates with and without 10 μg of Clavulanic acid. A tube containing about 2 ml of sterile normal saline is inoculated with a pure culture
growth until matching has occurred with 0.5 McFarland turbidity standard of approximately 1-2×10^8 CFU/ml. For each isolate one or more of the following cephalosporins disc ceftazidime (CAZ) 30 μg, cefotaxime (CTX) 30 μg and cefepime (FEP) was added to Mueller-Hinton agar plate seeded with bacterial suspension. On the same plate one or more of the antibiotics discs containing ceftazidime 30 μg+10 μg of clavulanic acid (CAL 30/10 μg), cefotaxime 30 μg+10 μg of clavulanic acid (CTL 30/10 μg) and cefepime 30 μg+10 μg of clavulanic acid (supplied by Liofilchem Co. Italy), were applied aseptically on the plate and pressed gently to agar surface using a sterile forceps. Within 15 min the plates were incubated at 37 °C for 16-18 hrs. A difference of ≥ 5 mm between the zone diameters of either of the cephalosporin disk and their respective cephalosporin/clavulanate disk is taken to be phenotypic confirmation of ESBLs production.

**Modified Hodge Test:**

The presence of carbapenemase enzyme was confirmed by Modified Hodge Test (MHT). A 1:10 dilution of inoculums of the indicator organism *E. coli* ATCC 25922, adjusted to a 0.5 McFarland turbidity standard, was used to inoculate the surfaces of plates containing Mueller-Hinton agar by swabbing. After the plates were allowed to stand at room temperature for 10 min, a disc containing meropenem (10 μg) were placed on the agar plates. Subsequently, three to five colonies of the test organisms (from an agar plate grown overnight) were inoculated onto the plate in a straight line out from the edge of the disk, using a loop. Quality control of the following organisms MHT Positive *Klebsiella pneumoniae* ATCC1705 and MHT Negative *Klebsiella pneumoniae* ATCC1706 were run with each batch of the test. Plates were examined after overnight incubation at 37°C. After 24 hrs, MHT Positive test showed a clover leaf-like indentation of the *Escherichia coli* 25922 growing along the test organism growth streak within the disk diffusion zone. MHT Negative test showed no growth of *Escherichia coli* 25922 along the test organism growth streak within the disk diffusion.

**Data Analysis:**

Data were analyzed using the statistical package for social science software (SPSS v. 20). A p-value of <0.05 was considered significant for all statistical tests in the present study.

**RESULTS**

A total of three hundred and eighty-four (n=384) different clinical specimens (urine 232(60%), wound swab 61 (16%), sputum 19(5%), and blood 72 (19%) as shown in figure 1. Specimens were collected from different Hospitals, these include Yastabshiroon Hospital, Khartoum 129(33.6%), Ribat Teaching Hospital, Khartoum 255(66.4%), 173 (45.0%) were Males, while 212 (55.0%) were females, 218(56.8%) were outpatients, 142(37%) were inpatients, 20(5.2%) ICU patients, and 4(1.0%) NICU patients. The age of patients included in this study ranged from 2 days to 90 years classified into five categories.
Frequency of Multi-Drug Resistant Enterobacter Species Isolated from Patients

**Bacterial Isolates:**

Identification of the isolates was carried out by using colony morphology on MacConkey agar media following incubation for 24 h at 37 °C, colonies were circular (1–2 mm in diameter), white, Opaque and elevated with regular margin lactose fermented, and on Chromogenic agar media Produced green color. As shown in Figure 2.

**Gram’s Stain and Biochemical Tests:**

Microscopic examination showed that these bacteria were Gram-negative rod-shaped (0.562–3 mm) and occurred singly, as shown in Figure 3-A.

Basic biochemical characterization of the 22 Enterobacter-like isolates was achieved using the Catalase test, Oxidase test, kiligler Iron agar test, Motility test, Citrate Utilization test, Urea hydrolysis test, and Indol test, as shown in Figure 3-B. Catalase activity was determined by observing bubble formation after dropping H2O2 on 24 hrs old biomass on nutrient agar. Oxidase activity was tested by using an oxidase reagent (bioMe’rieux), in this study showed that all Enterobacter-like isolates were motile, catalase positive, and oxidase negative, lactose and glucose fermented with gas and noH2s production on kiligler Iron agar. While 21(95.4%) isolates were Indol (negative), 16(72.7%) isolates were Citrate (positive), and 16(72.7%) isolates were Urease (negative).
Fig. 3: A: showing Gram-negative rod-shaped (0.562–3 mm) and occurred singly. B: 24 hr old culture of isolated bacteria on kiligler Iron ager test show lactose and glucose fermented with gas and no production of H2s, Citrate Utilization test (positive), Urea Hydrolysis Test (negative), and Indol test (negative).

**Antimicrobial Susceptibility Test:**

All the 22 *Enterobacter* spp isolates were resistant to Amoxicillin, Amoxyclav, Ceftriaxone, Cephotaxime, Ceftazidime, Cefotaxime, Chloramphnicol, Nitrofuratoin, and Vancomycin (100%). While 21(95.5%) isolates were sensitive to Amikacin, 4 (18.2%) to Cefepime and Tetracycline, 3(13.6%) to Co-trimoxazole, 9(40%) to Ciprofloxacin, 2(9.1%) to Gentamicin, 8 (36.4%) to Imipenem, and 13(59.1%) to Colistin, as exhibited in Table 1.

This study showed that all *Enterobacter* spp isolates (100%) were multidrug-resistant, The Prevalence rates of resistant isolates among antibiotic class were (Penicillin 100%, Cephalosporin 96.4%, Tetracycline group 100%, Aminoglycosides 47.7%, Sulfonamides and trimethoprin 86.4%, Nitrofuran 100%, Quinolone 72.75%, Glycopeptides 100%, Chloramphnicol 100%, Tetracycline 81.8% and Carbapenem 52.3%).

In this study, we have shown a high prevalence of ESBLs and carbapenemase enzymes produced by *Enterobacter* spp in Khartoum.
Table 1: Antimicrobial susceptibility profiles the isolates of Enterobacter-spp

<table>
<thead>
<tr>
<th>Frequency of MDR Enterobacter spp among Antibiotic classes</th>
<th>Antimicrobial agent</th>
<th>Sensitive Frequency (%)</th>
<th>Resistant Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin (100%)</td>
<td>Amoxicillin</td>
<td>0 (0.0%)</td>
<td>22 (100%)</td>
</tr>
<tr>
<td>Cephalosporin (96.4%)</td>
<td>Amoclave</td>
<td>0(0.0%)</td>
<td>22(100%)</td>
</tr>
<tr>
<td></td>
<td>Cefotaxime</td>
<td>0(0.0%)</td>
<td>22(100%)</td>
</tr>
<tr>
<td></td>
<td>Ceftazidime</td>
<td>0(0.0%)</td>
<td>22(100%)</td>
</tr>
<tr>
<td></td>
<td>Ceftriaxone</td>
<td>0(0.0%)</td>
<td>22(100%)</td>
</tr>
<tr>
<td></td>
<td>Cefepime</td>
<td>4(18.2%)</td>
<td>18(81.8%)</td>
</tr>
<tr>
<td></td>
<td>Cephotaxine</td>
<td>0(0.0%)</td>
<td>22(100.0%)</td>
</tr>
<tr>
<td>Sulfonamides and trimethoprim (86.4%)</td>
<td>Co-trimoxazole</td>
<td>3(13.6%)</td>
<td>19(86.4%)</td>
</tr>
<tr>
<td>Aminoglycosides (47.7%)</td>
<td>Amickacín</td>
<td>21(95.5%)</td>
<td>1(4.5%)</td>
</tr>
<tr>
<td></td>
<td>Gentamicin</td>
<td>2(9.1%)</td>
<td>20(90.9%)</td>
</tr>
<tr>
<td>Nitrofurane (100%)</td>
<td>Nitrofuratoin</td>
<td>0(0.0%)</td>
<td>22(100.0%)</td>
</tr>
<tr>
<td>Quinolone (72.75%)</td>
<td>Ciprofloxacin</td>
<td>11(50.0%)</td>
<td>11(50.0%)</td>
</tr>
<tr>
<td></td>
<td>Norofloxacin</td>
<td>1(4.5%)</td>
<td>21(95.5%)</td>
</tr>
<tr>
<td>Glycopeptides (100%)</td>
<td>Vancomycin</td>
<td>0(0.0%)</td>
<td>22(100.0%)</td>
</tr>
<tr>
<td>Chloramphenicol (100%)</td>
<td>Chloramphenicol</td>
<td>0(0.0%)</td>
<td>22(100.0%)</td>
</tr>
<tr>
<td>Tetracycline (81.8%)</td>
<td>Tetracycline</td>
<td>4(18.2%)</td>
<td>18(81.8%)</td>
</tr>
<tr>
<td>Carbapenem (52.3%)</td>
<td>Imipinem</td>
<td>8(36.4%)</td>
<td>14(63.6%)</td>
</tr>
<tr>
<td></td>
<td>Colistin</td>
<td>13(59.1%)</td>
<td>9(40.9%)</td>
</tr>
</tbody>
</table>

Fig. 4: Antimicrobial Susceptibility test by Kirby–Bauer disc diffusion technique.

Demographic Data of Patients with Enterobacter Spp Infections:

Among the 384 different clinical specimens, 22 isolates identified as Enterobacter spp, 11 (50%) were males while 11 (50%) were females. There was no significant difference in the distribution of isolates among the gender (p = 0.645).

The ages of patients were classified into five categories: the highest frequency was shown in the age group (15-30 years old, 46-60 years old, and age group >60 years old 6 (27.3%) the lowest frequency was shown in the age group <15 years old 1(4.5%), There was no significant difference in the distribution of isolates among the age group (p = 0.246). as shown in Table2.
Table 2: shows the demographic data of a patient with Enterobacter infection, including age and gender

<table>
<thead>
<tr>
<th>Gender</th>
<th>Frequency</th>
<th>Percent</th>
<th>P value</th>
<th>Age groups</th>
<th>Frequency</th>
<th>Percent</th>
<th>P value</th>
<th>Mean</th>
<th>Std. Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>11</td>
<td>50%</td>
<td>0.645</td>
<td>&gt;15</td>
<td>1</td>
<td>4.5%</td>
<td></td>
<td>48.6</td>
<td>23.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16-30</td>
<td>6</td>
<td>27.3%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31-45</td>
<td>3</td>
<td>13.6%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>46-60</td>
<td>6</td>
<td>27.3%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;60</td>
<td>22</td>
<td>100%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>11</td>
<td>50%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>22</td>
<td>100%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3 shows the distribution of Enterobacter spp among patient status, the frequency of patients suffering in different clinics (outpatient) was 7(31.8%), while 12(54.5%) were admitted to hospital(inpatient), and 3(13.6%) ICU patient. There was no significant difference in the distribution of isolates among the patient status group (p = 0.259).

<table>
<thead>
<tr>
<th>Patient status</th>
<th>Frequency</th>
<th>Percent</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outpatient</td>
<td>7</td>
<td>31.8%</td>
<td>0.259</td>
</tr>
<tr>
<td>Inpatient</td>
<td>12</td>
<td>54.5%</td>
<td></td>
</tr>
<tr>
<td>ICU</td>
<td>3</td>
<td>13.6%</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>22</td>
<td>100.0%</td>
<td></td>
</tr>
</tbody>
</table>

Frequency of Multi-Drug Resistant Enterobacter spp Infections Among Significant Growth:

A total of 384 (100%) clinical specimens were inoculated on MacConkey agar media and chromogenic agar media, 230 (60%) was no growth, while 154(40%) significant bacterial growth, the result showed a high frequency of Enterobacter spp 22(14%) {(9 (5.8%) urine, 11(7%) wound swab, 2(1.2%) sputum, 0(0%) blood)} among 154(40%) significant bacterial growth as shown in Table 4.

Table 4: Frequency of Enterobacter spp infections among significant growth.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Specimen</th>
<th>Total (%) of Significant growth</th>
<th>Enterobacter spp</th>
</tr>
</thead>
<tbody>
<tr>
<td>UTI</td>
<td>Urine</td>
<td>83 (54%)</td>
<td>9(5.8%)</td>
</tr>
<tr>
<td>Wound infection</td>
<td>Wound Swab</td>
<td>47(30.5%)</td>
<td>11(7.0%)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>Sputum</td>
<td>10(6.5%)</td>
<td>2(1.2%)</td>
</tr>
<tr>
<td>Septicemia</td>
<td>Blood</td>
<td>14(9.0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Total (%)</td>
<td></td>
<td>154(100%)</td>
<td>22(14.0%)</td>
</tr>
</tbody>
</table>

Frequency of Multi-Drug Resistant Enterobacter spp Among Other Isolated Bacteria:

Among 154 bacterial isolate 22(14.3%) were confirmed as Enterobacter spp, while E. coli 38(24.7%), Klebsiella spp 10(12.3), Staphylococcus spp 16(10.4%), Proteus spp 10(6.5%), and Pseudomonas spp 21(13.6%), E.fecales 13(8.4%), Candida spp 8(5.1%), and Moraxella spp 2(1.3%), Aceintobacter 2(1.3), Serratia, Citrobacter, and S.pyogen 1(0.7%). As many as 28(18.2 %) other species, as shown in Figure 5. Enterobacter spp is the second most common cause of bacterial infections.
Initial investigation showed that the etiological agents were Gram-stain-negative, rod-shaped isolates that possessed most of the morphological and phenotypic characteristics of the genus Enterobacter, but could not be unambiguously assigned to any currently known species.

**DISCUSSION**

Enterobacter species have been recognized as increasingly important pathogens in recent years. They have increased in incidence as causes of nosocomial infections in general (the third most common cause of nosocomial Gram-negative bacillary respiratory infections; as with other aerobic Gram-negative rods), (Mezzatesta et al., 2012).

In this study a total of three hundred and eighty-four (n=384) different clinical specimens (urine 232(60%), wound swab 61 (16%), sputum 19(5%), and blood 72 (19%). Specimens were collected from different Hospitals in Khartoum-Sudan, these include Yastabshiroon Hospital 129(33.6%), Ribat Teaching Hospital 255(66.4%), 173 (45.0%) were Males, while 212 (55.0%) were females. Among 154(40%) bacterial isolate 22(14.3%) were confirmed as Enterobacter spp, show11 (50%) were males, and 11(50%) were females; statistically there was no significant association (P-value > 0.05) between Enterobacter infections and gender (p = 0.645). The ages of patients in this study were classified into five categories: the highest frequency was shown in the adult groups including age group (15-30 years old, 46-60 years old, and age group >60 years old 6 (27%) the lowest frequency was shown in the children group <15 years old 1(4.5%). There was no significant association between Enterobacter infections and age groups (p = 0.246). These findings agree with a previous study conducted in Nigeria by (Mordi and Hugbo.2011) who recorded there was no significant difference in the distribution of isolates among the age groups (p > 0.05).

This study showed that the distribution of Enterobacter species isolates was 12(54.5%) in admitted hospital patients (inpatients) including intensive care unit patients 3(13.6%), while 7(31.8%) of outpatients accounted for the least frequent samples. There was no significant difference in the distribution of isolates among the patient status group (p = 0.259), these findings disagree with a previous study conducted in Kermanshah, Iran by (Zeinab Mohseni et al; 2021) who recorded most cases of positive
Enterobacter were isolated from ICUs (ICU, NICU, and PICU; 35.6%) and the emergency ward (bone marrow and kidney; 1.3%) and outpatients (9.2%) accounted for the least frequent samples.

In this study, most cases of positive Enterobacter were isolated from wound swab 11 (7%), urine 9 (5.8%), sputum 2 (1.2%), 0 (0%) blood, these findings disagree with a previous study conducted in Kermanshah, Iran by (Zeinab Mohseni et al; 2021) who recorded most cases of positive Enterobacter were isolated from urine (51.6%) and sputum samples (20.5%), while the positive cases isolated from vaginal and tissue biopsy samples (0.2%) were least frequent.

This study shows all Enterobacter spp isolates were resistant to Amoxicillin, Amoxyclav, Ceftriaxone, Cephotaxime, Ceftazidine, Cefotaxime, Chloramphenicol, Nitrofuratoin, and Vancomycin (100%). While (95.5%) isolate was sensitive to Amikacin, (18.2%) isolates were sensitive to Cefepime and Tetracycline, (13.6%) isolates were sensitive to Co-trimoxazole, (40%) isolates were sensitive to Ciprofloxacin, (9.1%) isolates were sensitive to Gentamicin, while (36.4%) isolates were sensitive to Imipenem, and (59.1%) isolates were sensitive to Colistin. In this study show all Enterobacter spp were multидrug resistant isolate (100%), the Prevalence rates of resistant isolate among antibiotic class were (Penicillin 100%, Cephalosporin 96.4%, Tetracycline group 100%, Aminoglycosides 47.7%, Sulfonamides and trimethoprin 86.4%, Nitrofurantoin 100%, Quinolone 72.75%, Glycopeptides 100%, Chloramphenicol 100%, Tetracycline 81.8% and Carbapenem 52.3%). These findings agree with a previous study conducted in Sudan by (Saeed and Musallam, 2011) who recorded that out of 389 specimens examined, 6 (1.5%) E. sakazakii was recovered. The results moreover revealed that the antimicrobial resistance of E. sakazakii was as follows; ceftazidime, amoxicillin, amoxyclav (100% each), co-trimoxazole, ticarcylene (83.3% each), chloramphenicol, tetracycline, ceftriaxone, nitrofuratoin, cephoxime, tobramycin (66.7% each), ciprofloxacin, amikacin and nalidixic acid (16.7% each). None of the isolates were found to be resistant to gentamicin. The results indicated for the first time the presence of E. sakazakii in the examined clinical specimens in Sudan. The occurrence was high and the antimicrobial resistance of the isolated E. sakazakii was also high. Also, these findings disagree with a previous study conducted in Iran by (Farzad Khademi et al 2022) who recorded pooled prevalence of Enterobacter species resistant to various antibiotics as follows: Imipenem 16.6%, Meropenem 16.2%, Aztreonam 40.9%, Ciprofloxacin 35.3%, Norfloxacin 31%, Levofloxacin 48%, Gentamicin 42.1%, Amikacin 30.3%, Tobramycin 37.2%, Tetracycline 50.1%, Chloramphenicol 25.7%, Timethoprim/Sulfamethoxazole 52%, Nalidixic acid 49.1%, Nitrofurantoin 43%, Ceftriaxone 49.3%, Cefixime 52.4%, Cefotaxime 52.7%, Ceftazidine 47.9%, Cefepime 43.6%, and Ceftizoxime 45.5%.

Prevalence rates of MDR and ESBL-producing Enterobacter species in Iran were 63.1% and 32.8%, respectively.

**Conclusion**

Enterobacter spp has emerged as a clinically significant cause of a wide variety of bacterial infections. There is still a lack of comprehensive molecular and clinical epidemiological analysis.

In this study, Enterobacter spp is the second most common cause of nosocomial Gram-negative bacillary infections (after E. coli).

The results of this study indicated the high prevalence of Enterobacter species resistant to the majority of assessed antibiotics. In addition, prevalence rates of ESBL and carbapenemases producing Enterobacter species and MDR strains were high in Khartoum- Sudan.

Finally, Enterobacter species was relatively high in Sudan, and it seems that carbapenems cannot be considered the best drugs of choice for the treatment of MDR and ESBL-producing Enterobacter species.
Amikacin is the best drug choice to treat *Enterobacter* infection.

**Recommendations**

We suggest the management of antibiotic prescription, launching and developing health education and infection control programs, continuous monitoring of drug resistance and evaluation of the therapeutic efficacy of new antimicrobial agents. To accurate identification of species and subspecies must be developed.

**Conflicts of Interest:**
The authors declare that they have no competing interests.

**Acknowledgements**
The authors are so grateful to the staff of the Yastabshiroon Hospital Laboratory, and Ribat Hospital Laboratory, ministry of higher education and scientific research for their help and support. The study was supported partially by the Dean of Scientific Research, Sudan University of Science and Technology, Sudan.

**REFERENCES**


emerging antibiotic resistance. 
*Future Microbiology*; 7(7):887-902.

Mohd-Khari, F.I., Karunakaran, R., Rosli, R.,
Tee Tay, S. (2016). Genotypic and 
phenotypic detection of ampC betalactamases in *Enterobacter* spp. 
isolated from a Teaching Hospital in 

Peymani, A., Farivar, T.N., Sanikhani, R., 
Emergence of TEM, SHV, and CTX-
M-extended spectrum beta-
lactamases and class 1 integron 
among *Enterobacter cloacae* 
isolates collected from hospitals of 
Tehran and Qazvin, Iran. 

Raphael M Mordi and Peter G Hugbo (2011), 
Frequency of Isolation of *Enterobacter* Species from a Variety 
of Clinical Specimens in a Teaching 
Hospitalin Nigeria, *Tropical Journal 
of Pharmaceutical Research*; 10 (6): 
793-800

report on *Enterobacter sakazakii* 
from Sudanese patients. *African 
journal of microbiology research*; 
5(16):2374-2379.

Singh, N.K., Bezdan, D., Checinska Sielaff, 
A., Wheeler, K., Mason, C.E., 
Venkateswaran, K. (2018). Multi-
drug resistant *Enterobacter bugandensis* species isolated from 
the International Space Station and 
comparative genomic analyses with 
human pathogenic strains. *BMC 
Microbiology*; 18:175. doi: 10.1186/ 
s12866-018-1325-2.

*Enterobacter sichuanensis* sp. nov., 
recovered from human urine. 
*International Journal of Systematic 
and Evolutionary Microbiology*; 68(12):3922-3927.

Zeinab Mohseni Afshar, Ronak milady, 
Alireza janbakhsh, Feizollah 
Mansouri; et al (2021). The 
Prevalence and Pattern of Enterobacter Antibiotic Resistance 
in the Patients Admitted to Imam 
Reza Hospital in Kermanshah, Iran 
(2016-2018), *Journal of Kermanshah University of Medical 